September 21, 2018 / 11:45 AM / 3 months ago

BRIEF-Abbvie Receives Positive CHMP Opinion Fo Chemotherapy-Free Combination Of Venclyxto With Rituximab

Sept 21 (Reuters) - AbbVie Inc:

* ABBVIE RECEIVES POSITIVE CHMP OPINION FOR A NOVEL, CHEMOTHERAPY-FREE COMBINATION OF VENCLYXTO® (VENETOCLAX TABLETS) WITH RITUXIMAB AS A TREATMENT WITH A FIXED DURATION FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

* ABBVIE - SAFETY PROFILE OF COMBINATION OF VENCLYXTO PLUS RITUXIMAB IS CONSISTENT WITH KNOWN SAFETY PROFILE OF EACH MEDICINE ALONE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below